Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ziopharm: 2Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $18.6 million in its second quarter.

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron's Libtayo -

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Names James Huang to Board of Directors

- Industry veteran entrepreneur with 20+ years' experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech -

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo(R) in Patients with Glioblastoma

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled...

ZIOP : 3.32 (+3.75%)
Do Options Traders Know Something About Ziopharm Oncology (ZIOP) Stock We Don't?

Investors need to pay close attention to Ziopharm Oncology (ZIOP) stock based on the movements in the options market lately.

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June, M.D., as Chairman of its newly formed Scientific...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy:...

ZIOP : 3.32 (+3.75%)
SmarTrend Watching for Potential Rebound in Shares of Ziopharm Oncolog After 1.35% Loss

Ziopharm Oncolog (NASDAQ:ZIOP) traded in a range yesterday that spanned from a low of $2.89 to a high of $3.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $2.90...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology

- Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile -

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Announces Management Transition

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a consultant to Ziopharm and will continue to help...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health...

ZIOP : 3.32 (+3.75%)
Ziopharm: 1Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $18.3 million in its first quarter.

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update

- Regulatory discussions with FDA advance Ziopharm TCR-T IND process -

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in combination...

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a corporate update and discuss financial results...

ZIOP : 3.32 (+3.75%)
Ziopharm: 4Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Monday reported a fourth-quarter loss of $15.7 million, after reporting a profit in the same period a year earlier.

ZIOP : 3.32 (+3.75%)
Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019

- Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 -

ZIOP : 3.32 (+3.75%)

Van Meerten Stock Picks

The 5 Best MidCaps
I wanted to find the 5 Mid Caps that have had the best momentum over the past year so I used Barchart to sort the S&P 400 MidCap Stock Index for the stocks with the highest Weighted Alpha and technical buying signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar